Equities

Indoco Remedies Ltd

INDOCO:NSI

Indoco Remedies Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)311.30
  • Today's Change-0.80 / -0.26%
  • Shares traded70.60k
  • 1 Year change-8.37%
  • Beta0.6237
Data delayed at least 15 minutes, as of May 24 2024 10:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Indoco Remedies Limited is an India-based manufacturer of pharmaceutical products. The Company is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The Company offers medicines in multiple therapeutic categories, such as diabetology, respiratory, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders and primary care medicine. Its products/brands include Cyclopam, Sensodent-K, Karvol Plus, Sensoform, Cital UTI, Kidodent, Rexidin M, Lignox A, Dentogel, Aloja, Homide, Renolen, Noxa, Dexoren - S, Aloja M, ATM, Febrex Plus, Sensodent-KF, SM Fibro, MCBM 69, Cal Aid, Snowdent, Dropizin, Zincoren, Coloferrin, Bfloren, RR Sensoform Dental, Mofloren-D, and Tuspel among others. The Company caters to both domestic and international markets. Its subsidiaries include Xtend Industrial Designers and Engineers Pvt Ltd, Indoco Remedies Czech sro, and Indoco Remedies UK Limited.

  • Revenue in INR (TTM)18.17bn
  • Net income in INR984.70m
  • Incorporated1947
  • Employees6.10k
  • Location
    Indoco Remedies Ltd166 Indoco HouseCst Road, Santacruz EastMUMBAI 400098IndiaIND
  • Phone+91 2 226541851
  • Fax+91 2 226523980
  • Websitehttps://www.indoco.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
INDOCO:NSI since
announced
Transaction
value
FPP Holding Co LLCAnnounced06 Jun 202306 Jun 2023Announced-6.94%4.00m
Data delayed at least 15 minutes, as of May 24 2024 10:35 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Themis Medicare Ltd3.82bn435.24m19.60bn996.0045.125.1935.155.144.724.7241.4141.030.70671.962.36--8.0611.1211.0716.4664.1961.4911.4014.961.44--0.20238.287.7415.75-23.51--26.73--
Amrutanjan Health Care Ltd3.94bn440.09m21.28bn575.0048.69--42.695.3915.1315.13135.41--------6,860,612.00--17.04--21.2249.5154.0811.1613.37--341.76--17.21-6.4611.37-40.7114.7223.8710.64
Suven Life Sciences Ltd116.93m-1.05bn21.40bn132.00--7.93--183.05-4.82-4.820.535912.380.0347--11.17---31.19-46.46-32.37-50.52-----898.63-787.6118.94-849.160.0026---13.64-47.2311.15------
Solara Active Pharma Sciences Ltd14.07bn-3.08bn22.57bn2.36k------1.60-78.92-78.92360.06--------5,958,916.00--2.68--4.1040.4744.49-21.884.58---1.67--10.1013.8322.6161.86--26.23--
RPG Life Sciences Limited5.82bn876.60m24.68bn1.17k28.156.5823.564.2453.0153.01351.99226.651.251.8813.45--18.8116.0725.1021.7768.3064.0415.0611.991.50246.840.0029.2713.5012.0129.6051.9828.6046.14
Morepen Laboratories Ltd16.90bn961.60m25.46bn1.65k26.493.0019.571.511.881.8833.1116.581.414.455.74--8.047.9011.5013.3437.1533.655.725.491.5933.730.0331--19.2517.08148.6327.2247.03--
SeQuent Scientific Ltd13.70bn-358.69m27.43bn478.00--4.1885.932.00-1.45-1.4556.2726.370.89252.194.05---1.931.09-3.271.7644.5342.74-2.161.180.76020.13760.4062---3.605.6870.40--6.96--
Innova Captab Ltd-100.00bn-100.00bn28.40bn--------------------------------------------------15.72--6.26------
Indoco Remedies Ltd18.17bn984.70m28.77bn6.10k29.672.5915.231.5810.5210.52193.15120.380.95571.654.80--5.106.887.029.8569.2366.665.346.930.98254.010.37712.678.9113.41-30.78--34.5437.97
Jeena Sikho Lifecare Ltd-100.00bn-100.00bn29.55bn1.23k--93.46----------12.72------------------------0.8228--0.2681--43.84--77.37------
Supriya Lifescience Ltd5.54bn1.20bn29.59bn392.0024.56--21.875.3414.9714.9768.93--------14,144,410.00--20.77--29.0661.9455.8321.7224.33--63.63--2.02-13.0416.70-40.8159.4185.55--
Dishman Carbogen Amcis Ltd25.80bn-1.54bn30.31bn1.30k----20.571.18-9.84-9.84164.35--------19,919,850.00--0.4699--0.566576.9374.36-5.981.82---0.1245--202.7612.727.32-265.46--21.54--
Gufic BioSciences Ltd7.85bn841.95m34.50bn1.63k39.91--32.714.408.628.6280.38--------4,820,074.00--12.30--23.0851.0844.9110.739.84--8.22--1.39-11.3617.47-16.8437.0686.8214.87
Hikal Ltd17.85bn696.00m37.00bn2.14k53.123.1219.772.075.655.65144.7796.320.73252.663.60--2.865.074.037.5153.7947.223.905.860.87612.650.407716.88-11.792.34-11.20-7.559.720.00
Data as of May 24 2024. Currency figures normalised to Indoco Remedies Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

18.04%Per cent of shares held by top holders
HolderShares% Held
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Apr 20244.58m4.97%
quant Money Managers Ltd.as of 30 Apr 20244.20m4.56%
DSP Asset Managers Pvt. Ltd.as of 30 Apr 20241.69m1.84%
ICICI Prudential Asset Management Co. Ltd.as of 30 Apr 20241.65m1.79%
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Apr 20241.50m1.63%
Franklin Templeton Asset Management (India) Pvt Ltd.as of 30 Apr 20241.36m1.48%
UTI Asset Management Co. Ltd. (Investment Management)as of 30 Apr 2024724.45k0.79%
Dimensional Fund Advisors LPas of 09 May 2024483.54k0.53%
Tata Asset Management Ltd.as of 30 Apr 2024276.85k0.30%
Fiduciary Management, Inc.as of 29 Feb 2024165.42k0.18%
More ▼
Data from 31 Mar 2024 - 16 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.